1
|
Vassal G, Kozhaeva O, Griskjane S, Arnold F, Nysom K, Basset L, Kameric L, Kienesberger A, Kamal S, Cherny N, Bricalli G, Latino N, Kearns P. Access to essential anticancer medicines for children and adolescents in Europe. Ann Oncol 2021; 32:560-568. [PMID: 33388384 DOI: 10.1016/j.annonc.2020.12.015] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2020] [Revised: 12/16/2020] [Accepted: 12/20/2020] [Indexed: 01/15/2023] Open
Abstract
BACKGROUND Essential anticancer medicines are an indispensable component of multidisciplinary treatment of paediatric malignancies. A European Society for Medical Oncology (ESMO) study reported inequalities in the availability of anticancer medicines for adult solid tumours and provided a model for the present survey. The aim of this survey was to assess the accessibility of essential medicines used in paediatric cancer patients aged 0 to 18 years across Europe from 2016 to 2018. METHODS A list of medicines was drawn with input from the European Society for Paediatric Oncology (SIOP Europe) Clinical Research Council referring to the World Health Organization Model List of Essential Medicines for Children (WHO EMLc) 2017. A survey was sent to nominated national clinician and pharmacist rapporteurs and parent associations in up to 37 countries; answers were obtained from 34 countries. RESULTS The full survey list contained 68 medicines, including 24 on the WHO EMLc 2017. Health professionals reported that 35% of all medicines were prescribed off-label in at least one country and that 44% were always available in >90% of countries. Only 63% of the EMLc 2017 medicines were reported as always available. The main determinant of unavailability was shortages, reported for 72% of medicines in at least one country. Out-of-pocket costs were reported in eight countries. Twenty-seven percent of orally administered medicines were never available in child-friendly formulations. Parents detailed individual efforts and challenges of facilitating ingestion of oral medicines as prescribed. Inequalities in access to pain control during procedures were reported by parents across Europe. CONCLUSIONS Children and adolescents with cancer in Europe experience lack of access to essential medicines. Urgent actions are needed to address shortages, financial accessibility, availability of safe age-appropriate oral formulations, and pain management across Europe.
Collapse
Affiliation(s)
- G Vassal
- Paediatric Oncology Department, Gustave Roussy, Villejuif, France; Paris-Sud University, Orsay, France; European Society for Paediatric Oncology (SIOP Europe), Brussels, Belgium.
| | - O Kozhaeva
- Policy Department, SIOP Europe, Brussels, Belgium
| | - S Griskjane
- Children's Clinical University Hospital, Riga, Latvia; European Society of Oncology Pharmacy (ESOP), Luxembourg
| | - F Arnold
- Childhood Cancer International - Europe (CCI-E), Montpellier, France
| | - K Nysom
- Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark; SIOP Europe, Brussels, Belgium
| | - L Basset
- CCI-E, Madrid, Spain; Universitat Politècnica de València, Valencia, Spain
| | - L Kameric
- CCI-E, Sarajevo, Bosnia and Herzegovina
| | | | - S Kamal
- Department of Pharmaceutical Services, Children's Cancer Hospital, Cairo, Egypt; ESOP, Luxembourg
| | - N Cherny
- Cancer Pain and Palliative Medicine Service, Department of Medical Oncology, Shaare Zedek Medical Center, Jerusalem, Israel; European Society for Medical Oncology (ESMO), Lugano, Switzerland
| | - G Bricalli
- European Society for Medical Oncology (ESMO), Lugano, Switzerland
| | - N Latino
- European Society for Medical Oncology (ESMO), Lugano, Switzerland
| | - P Kearns
- Institute of Cancer and Genomic Sciences, NIHR Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK; SIOP Europe, Brussels, Belgium
| |
Collapse
|
2
|
Basset L, Lassale B, Succamiele L, Moya-Macchi M. [Intravenous lines in transfusion and their medical devices]. Transfus Clin Biol 2018; 25:276-280. [PMID: 30172562 DOI: 10.1016/j.tracli.2018.08.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2018] [Accepted: 08/02/2018] [Indexed: 01/14/2023]
Abstract
Treatment by blood transfusion first requires an intravenous cannula. Professionals remember the optimal diameter for transfusion (16 to 18G). Practices differ according to the department concerned. Neonatology and paediatric wards use precision filters and put in fine cannulas (24G) with the constraint that this restricts transfusion flow rate. In haematology and oncology departments, the state of the patient's veins has to be considered when administering chemotherapy which may be toxic for vascular endothelium and the implantation of a venous port by a critical care anaesthetist may be suggested. Emergency departments use central venous catheters, blood warmers and, exceptionally, intraosseous infusion which is now being used again. Haemodialysis requires repeated vascular access making the creation of arteriovenous fistula necessary. We wanted to have an overview of all the different techniques potentially used in the departments of a health institution. These medical devices are managed by the pharmacies in our institutions.
Collapse
Affiliation(s)
- L Basset
- Service d'hémovigilance et de sécurité transfusionnelle AP-HM, 270, boulevard Sainte-Marguerite, Pavillon 9, 13009 Marseille, France.
| | - B Lassale
- Service d'hémovigilance et de sécurité transfusionnelle AP-HM, 270, boulevard Sainte-Marguerite, Pavillon 9, 13009 Marseille, France
| | - L Succamiele
- Coordination régionale de matériovigilance et de réactovigilance PACA, 270, boulevard Sainte-Marguerite, Pavillon 9, 13009 Marseille, France
| | - M Moya-Macchi
- Service d'hémovigilance et de sécurité transfusionnelle AP-HM, 270, boulevard Sainte-Marguerite, Pavillon 9, 13009 Marseille, France
| |
Collapse
|
3
|
Vassal G, Schrappe M, Pritchard-Jones K, Arnold F, Basset L, Biondi A, Bode G, Eggert A, Hjorth L, Kamerić L, Karner S, Kearns P, Kienesberger A, Kowalczyk J, Lack P, Perilongo G, Sullivan R, Tsirou A, Kamerić N, Essiaf S, Ladenstein R. 1407 The European Strategic Plan for children and adolescents with cancer. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30578-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
4
|
Basset L, Roubaud P, Zampa S, Moya-Macchi M, Lassale B. Apport du développement professionnel continu dans la formation continue. Infirmière à l’AP–HM. Transfus Clin Biol 2014. [DOI: 10.1016/j.tracli.2014.08.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
5
|
Basset L, Masson J, Bernoussi A, Wawrzyniak M. Cancers et terrain familial: impacts psychologiques du risque de transmission d’un gène muté. PSYCHO-ONCOLOGIE 2013. [DOI: 10.1007/s11839-013-0414-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
6
|
Oriol P, Redon C, Basset L, Garel MC, Courbon G, Pozzetto B. Intérêt de l’utilisation de l’outil « Blood Quizz » de l’AP–HM pour optimiser la formation des soignants du CHU de Saint-Étienne à la sécurité transfusionnelle. Transfus Clin Biol 2013. [DOI: 10.1016/j.tracli.2013.03.274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
7
|
Basset L, Di Majo P, Moya M, Artero N, Lassale B. Blood-Quizz : outil d’autoévaluation en transfusion à l’Assistance publique–Hôpitaux de Marseille (AP–HM). Transfus Clin Biol 2010. [DOI: 10.1016/j.tracli.2010.09.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
8
|
Lassale B, Artero N, Basset L, Moya M. Transfusions de produits sanguins labiles nocturnes non-urgentes en l’absence du médecin prescripteur du service : analyse en 2009 et mise en place de mesures correctives. Transfus Clin Biol 2010. [DOI: 10.1016/j.tracli.2010.09.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
9
|
Basset L, Ennamany R, Portail JP, Kretz O, Deffieux G, Badoc A, Guillemain B, Creppy EE. Effects of bolesatine on a cell line from the SP2/O thymic lymphosarcoma. Toxicology 1995; 103:121-5. [PMID: 8545844 DOI: 10.1016/0300-483x(95)03113-t] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Bolesatine, a toxic protein isolated from Boletus satanas Lenz inhibits in vitro protein synthesis in a concentration-dependent manner in a cell line from a radiation-induced thymic lymphosarcoma (SP2/O) with a 50% inhibitory concentration (IC50) of 9.5 nM (0.6 microgram/ml). In vivo, an i.p. single injection of bolesatine, corresponding to 1/6 and 1/10 of 24-h 50% lethal dose, in Balb/c mice having ascitic tumour induced by the i.p. preinjection of SP2/O cells allows a remission of 50% and 30%, respectively. Treated mice survived 120 days after the treatment, i.e. 90 days after the death of control animals.
Collapse
Affiliation(s)
- L Basset
- University of Bordeaux 2, Faculty of Pharmaceutical Sciences, Laboratory of Toxicology and Applied Hygiene, France
| | | | | | | | | | | | | | | |
Collapse
|